Novo Nordisk’s CagriSema Disappoints Again
The REDEFINE 2 study saw CagriSema fail to outshine Lilly’s tirzepatide in weight loss for overweight patients with diabetes, leaving its rival still in the driving seat.
The REDEFINE 2 study saw CagriSema fail to outshine Lilly’s tirzepatide in weight loss for overweight patients with diabetes, leaving its rival still in the driving seat.